For the first time, a drug targeting a protein that drives breast cancer growth has been shown to work against tumours with very low levels of the protein
A study by a multidisciplinary team at Weill Cornell Medicine has identified a new protein variant that underlies the ability of gastric cancers to resist an otherwise effective family of chemotherapy drugs.